Project: Development of next-generation treatment for allergies: targeted glycan-allergen immunotherapy
The TARGIT project will develop a next-generation allergy vaccine to treat grass-pollen induced allergic rhinitis and asthma effectively and life-long. The vaccine is based on unique glycans, covalently linked to clinically relevant grass pollen derived peptides. We will generate Proof-of-Concept for the product, entering clinical testing with the large pharma partner Allergopharma directly after this project, as well as for the core technology providing direct spin-off towards other allergens.
Acronym | TARGIT (Reference Number: 10545) |
Duration | 01/11/2016 - 01/11/2019 |
Project Topic | Biological Sciences / Technologies |
Network | Eurostars 2 |
Call | Eurostars Cut-Off 5 |
Project partner
Number | Name | Role | Country |
---|---|---|---|
24446 | DC4U BV | Coordinator | Netherlands |
24447 | piCHEM Forschungs- und Entwicklungs GmbH | Partner | Austria |
24448 | Pharmacelsus GmbH | Partner | Germany |
24449 | Academisch Ziekenhuis Groningen (University Medical Center Groningen; UMCG) | Partner | Netherlands |
24450 | Fraunhofer Gesellschaft, Fraunhofer Institute for Toxicology and Experimental Medicine | Partner | Germany |
24451 | Allergopharma GmbH & Co. KG | Partner | Germany |